IP Library Granted Patent US 10,350,282
Granted Patent B2
US 10,350,282 · App. 15/333,518 · Granted Jul 16, 2019

Mesothelin vaccines and model systems

Inventors: Elizabeth A. Jaffee (Lutherville, MD); Tzyy-Choou Wu (Stevenson, MD); Chien-Fu Hung (Timonium, MD); Ralph Hruban (Baltimore, MD)
Assignee: The Johns Hopkins University
A61K39/0208A61K39/0011C07K7/06C07K16/30C12N15/74C12N15/8509A01K2267/0331A61K2039/505A61K2039/5154A61K2039/52A61K2039/522A61K2039/523A61K2039/53A61K2039/55511A61K2039/55522A61K2039/57A61K2039/6031C07K14/4748C12N2710/16522C12N2740/13043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,350,282
App. No.
15/333,518
Granted
Jul 16, 2019
Kind
B2
Abstract

Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.

Claims (5)

1. A method of inducing a T-cell response to a pancreatic tumor, the method comprising:

administering to a patient who has said tumor or who has had said tumor removed, a vaccine comprising Listeria monocytogenes bacteria that express human leukocyte antigen (HLA)-restricted mesothelin peptides.

2. The method of claim 1 wherein mesothelin-specific CD8 + T cells are induced by said vaccine.

3. The method of claim 1 wherein the vaccine is administered in sufficient amount to induce tumor regression.

4. The method of claim 1 wherein the vaccine is administered in sufficient amount to keep the patient tumor-free after removal of the tumor.

Continuity (11)
Division 15069047 · Mar 14, 2016
Division 14042812 · Oct 1, 2013
Division 13293357 · Nov 10, 2011
Continuation 12049763 · Mar 17, 2008
Continuation In Part 10618088 · Jul 14, 2003
Provisional Application 60918267 · Mar 15, 2007
Provisional Application 60475783 · Jun 5, 2003
Provisional Application 60414931 · Sep 30, 2002
Provisional Application 60398217 · Jul 24, 2002
Provisional Application 60395556 · Jul 12, 2002
Related Publication 20170072040A1 · Mar 16, 2017